The clinical perspective on late-onset depression in European real-world treatment settings

Lucie Bartova,Gernot Fugger,Markus Dold,Alexander Kautzky,Isabella Bairhuber,Philipp Kloimstein,Giuseppe Fanelli,Raffaella Zanardi,Ana Weidenauer,Dan Rujescu,Daniel Souery,Julien Mendlewicz,Joseph Zohar,Stuart Montgomery,Chiara Fabbri,Alessandro Serretti,Siegfried Kasper
DOI: https://doi.org/10.1016/j.euroneuro.2024.03.007
IF: 5.415
2024-04-30
European Neuropsychopharmacology
Abstract:The clinical phenotype of the so-called late-onset depression (LOD) affecting up to 30% of older adults and yielding heterogeneous manifestations concerning symptoms, severity and course has not been fully elucidated yet. This European, cross-sectional, non-interventional, naturalistic multicenter study systematically investigated socio-demographic and clinical correlates of early-onset depression (EOD) and LOD (age of onset ≥ 50 years) in 1410 adult in- and outpatients of both sexes receiving adequate psychopharmacotherapy. In a total of 1329 patients (94.3%) with known age of disease onset, LOD was identified in 23.2% and was associated with unemployment, an ongoing relationship, single major depressive episodes, lower current suicidal risk and higher occurrence of comorbid hypertension. In contrast, EOD was related to higher rates of comorbid migraine and additional psychotherapy. Although the applied study design does not allow to draw any causal conclusions, the present results reflect broad clinical settings and emphasize easily obtainable features which might be characteristic for EOD and LOD. A thoughtful consideration of age of onset might, hence, contribute to optimized diagnostic and therapeutic processes in terms of the globally intended precision medicine, ideally enabling early and adequate treatment allocations and implementation of respective prevention programs.
pharmacology & pharmacy,neurosciences,psychiatry,clinical neurology
What problem does this paper attempt to address?